From Biomarkers to Diagnostics: Personalized Medicine in Hepatocellular CarcinomaMonday, 27 October 2014 at 11:00 Add to Calendar ▼SELECTBIOenquiries@selectbiosciences.com The development of personalized therapies for hepatocellular carcinoma (HCC) has been challenging because of the complexity and heterogeneity of this disease. We will present the biomarker analysis of a global phase II clinical trial with an immunotherapy targeting glypican-3, a well-known prognostic factor in HCC. Our research identified a potential biomarker that could be used to select patients benefiting from this therapy. We will show analyses results as well as assay development process leading to biomarker validation. |